AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11104592 — intervention group
Group type: COMPARATOR
Intervention: Control group (crystalloid solutions only)
Number of subjects: 80
Study 9557493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (early therapeutic intervention)
Number of subjects: 0
Study 9557493 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged breast feeding
Number of subjects: 0
Study 9557493 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 8142781 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (eutectic mixture of local anesthetics) applied for 3 minutes
Number of subjects: 0
Study 8142781 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study 2873397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral B subunit killed whole‐cell (BS‐WC) vaccine
Number of subjects: 63498
Study 2873397 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole‐cell (WC) vaccine
Number of subjects: 63498
Study 2873397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63498
Study 30614403 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE intervention
Number of subjects: 51
Study 30614403 — intervention group
Group type: COMPARATOR
Intervention: Control (Facebook) group
Number of subjects: 51
Study 26469395 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, 20 minutes for 5 consecutive days)
Number of subjects: 20
Study 26469395 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study 26469395 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 20
Study 25530675 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) at 1 mA for 20 minutes over the left dorsolateral prefrontal cortex (F3) for 5 consecutive days
Number of subjects: 20
Study 25530675 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS stimulation
Number of subjects: 20
Study 23116986 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 881
Study 23116986 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 881
Study 20474068 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with T1D
Number of subjects: 2160
Study 20474068 — intervention group
Group type: COMPARATOR
Intervention: Mothers without T1D
Number of subjects: 2160
Study 19047671 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 ppm fluoride dentifrice
Number of subjects: 0
Study 19047671 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,100 ppm fluoride dentifrice
Number of subjects: 0
Study 19047671 — intervention group
Group type: EXPERIMENTAL
Intervention: No fluoride dentifrice
Number of subjects: 0
Study 15670563 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methionine administration
Number of subjects: 0
Study 15670563 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12601318 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Rhinocort AQUA)
Number of subjects: 20
Study 12601318 — intervention group
Group type: COMPARATOR
Intervention: Mometasone (Nasonex)
Number of subjects: 20
Study 10488698 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV seropositive women with detectable HCV RNA in serum (n = 16)
Number of subjects: 22
Study 10488698 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV seropositive non-viremic patients (n = 6)
Number of subjects: 22
Study 10488698 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 HCV seronegative women)
Number of subjects: 22
Study 10488698 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of the women tested (n = 10)
Number of subjects: 22
Study 8947993 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 5, 10, 25, 50, or 100 mg
Number of subjects: 0
Study 8947993 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac in mouse pain model
Number of subjects: 0
Study 8947993 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 50 mg
Number of subjects: 0
Study 1915199 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein hydrolysate diet
Number of subjects: 32
Study 1915199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact protein diet
Number of subjects: 32
Study 1915199 — intervention group
Group type: COMPARATOR
Intervention: Both diets
Number of subjects: 32
Study 31564057 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 250
Study 31564057 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab with topical corticosteroids
Number of subjects: 250
Study 29483085 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie vegetarian diet (Vd)
Number of subjects: 118
Study 29483085 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie Mediterranean diet (MD)
Number of subjects: 118
Study 27759648 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative acute lung injury (ALI) assessment
Number of subjects: 130
Study 27759648 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative clinical baselines and serum variables assessment
Number of subjects: 130
Study 27759648 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple logistic regression analysis
Number of subjects: 130
Study 25099941 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Walking Training (IWT)
Number of subjects: 32
Study 25099941 — intervention group
Group type: COMPARATOR
Intervention: Continuous Walking Training (CWT)
Number of subjects: 32
Study 25099941 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 32
Study 22039269 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (CS injection)
Number of subjects: 137
Study 22039269 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous release
Number of subjects: 137
Study 22039269 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 137
Study 20929584 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) - 429‐559 kcal/day liquid formula for 4 weeks after quitting
Number of subjects: 30
Study 20929584 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Dietary and Activity Planning (IDAP) - goal-setting with a daily reduction of 600 kcal
Number of subjects: 30
Study 20929584 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary advice (Control)
Number of subjects: 30
Study 20929584 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 6 and 12 months
Number of subjects: 30
Study 20929584 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight, waist and hip circumference, percentage body fat
Number of subjects: 30
Study 20929584 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence confirmed by CO < 10 ppm
Number of subjects: 30
Study 17804169 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 82
Study 17804169 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 82
Study 17180869 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty acid supplementation
Number of subjects: 0
Study 17180869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12831415 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat
Number of subjects: 14
Study 12831415 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 14
Study 10771456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg day(‐1) on days 9‐11 followed by 80 mg day(‐1) on days 12‐15
Number of subjects: 25
Study 10771456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9387729 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhenkeling oral liquor (ZKL group)
Number of subjects: 170
Study 9387729 — intervention group
Group type: COMPARATOR
Intervention: Pectoral syrup (control group)
Number of subjects: 170
Study 1343611 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral low-dose (7.5 mg) methotrexate (MTX) for 2 years
Number of subjects: 100
Study 1343611 — intervention group
Group type: COMPARATOR
Intervention: Identical-appearing placebo for 2 years
Number of subjects: 100
Study 1343611 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral low-dose (7.5 mg) methotrexate (MTX)
Number of subjects: 100
Study 1343611 — intervention group
Group type: COMPARATOR
Intervention: Identical-appearing placebo
Number of subjects: 100
Study 2864738 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric inhibitory polypeptide (GIP) in pharmacological doses
Number of subjects: 6
Study 2864738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK) in pharmacological doses
Number of subjects: 6
Study 2864738 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin in pharmacological doses
Number of subjects: 6
Study 30880951 — intervention group
Group type: EXPERIMENTAL
Intervention: batefenterol 37.5 µg
Number of subjects: 323
Study 30880951 — intervention group
Group type: EXPERIMENTAL
Intervention: batefenterol 75 µg
Number of subjects: 323
Study 30880951 — intervention group
Group type: EXPERIMENTAL
Intervention: batefenterol 150 µg
Number of subjects: 323
Study 30880951 — intervention group
Group type: EXPERIMENTAL
Intervention: batefenterol 300 µg
Number of subjects: 323
Study 30880951 — intervention group
Group type: EXPERIMENTAL
Intervention: batefenterol 600 µg
Number of subjects: 323
Study 30880951 — intervention group
Group type: EXPERIMENTAL
Intervention: umeclidinium/vilanterol (UMEC/VI) 62.5/25 µg
Number of subjects: 323
Study 30880951 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 323
Study 29526609 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (iENGAGE) focusing on retention in care and ART adherence skills during the first year of HIV care.
Number of subjects: 0
Study 27197523 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus tamoxifen for 2 years and 5 years of tamoxifen
Number of subjects: 1483
Study 27197523 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone for 5 years
Number of subjects: 1483
Study 24344049 — intervention group
Group type: EXPERIMENTAL
Intervention: Mangifera indica extract (Vimang tablets, 900 mg/day) combined with methotrexate (MTX, 12.5 mg/week)
Number of subjects: 20
Study 24344049 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX, 12.5 mg/week) without Vimang extract
Number of subjects: 20
Study 22743029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 36
Study 22743029 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 36
Study 22743029 — intervention group
Group type: COMPARATOR
Intervention: Sham Cryotherapy
Number of subjects: 36
Study 22743029 — intervention group
Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 36
Study 20585287 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration Group
Number of subjects: 34
Study 20585287 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 34
Study 17474183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic agents
Number of subjects: 0
Study 17474183 — intervention group
Group type: EXPERIMENTAL
Intervention: NMDA agonists
Number of subjects: 0
Study 17474183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive interventions including rehabilitation pharmacotherapy
Number of subjects: 0
Study 17474183 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs strategically coupled to cognitive-behavioral treatments
Number of subjects: 0
Study 17474183 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of vascular risk factors
Number of subjects: 0
Study 16136052 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy started within 3 months of surgery (CMF, CMF i.v., cyclofosfamide, epirubicin, and 5‐fluorouracil)
Number of subjects: 7501
Study 16136052 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy started after 3 months of surgery (delayed start)
Number of subjects: 7501
Study 12182269 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' expectancies of treatment effectiveness
Number of subjects: 151
Study 12182269 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' expectancies for patient improvement
Number of subjects: 151
Study 12182269 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of therapeutic alliance
Number of subjects: 151
Study 10460813 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency revascularization
Number of subjects: 302
Study 10460813 — intervention group
Group type: COMPARATOR
Intervention: Initial medical stabilization
Number of subjects: 302
Study 8552460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichorhinic mixtures with delays of 200 to 400 ms
Number of subjects: 0
Study 8552460 — intervention group
Group type: COMPARATOR
Intervention: Synchronous mixtures
Number of subjects: 0
Study 8552460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichorhinic mixtures
Number of subjects: 0
Study 8552460 — intervention group
Group type: COMPARATOR
Intervention: Monorhinic mixtures
Number of subjects: 0
Study 2140838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg/day (KE40)
Number of subjects: 29
Study 2140838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 80 mg/day (KE80)
Number of subjects: 29
Study 2140838 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 29
Study 507944 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment and oral administration of BCG
Number of subjects: 31
Study 507944 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment only
Number of subjects: 31
Study 30715090 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D3/d
Number of subjects: 100
Study 30715090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 28397242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib with concomitant anticoagulation (11%)
Number of subjects: 327
Study 28397242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib with concomitant antiplatelet use (34%)
Number of subjects: 327
Study 28397242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib with concomitant anticoagulant or antiplatelet agents (175 patients)
Number of subjects: 327
Study 28397242 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib alone (without anticoagulants or antiplatelets)
Number of subjects: 327
Study 26362110 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral collagen peptide supplementation
Number of subjects: 0
Study 26362110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo collagen peptide supplementation
Number of subjects: 0
Study 23017096 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop signal intervention
Number of subjects: 0
Study 23017096 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 21586691 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute
Number of subjects: 353
Study 21586691 — intervention group
Group type: COMPARATOR
Intervention: Endeavor
Number of subjects: 353
Study 21586691 — intervention group
Group type: COMPARATOR
Intervention: ZoMaxx
Number of subjects: 353
Study 21586691 — intervention group
Group type: COMPARATOR
Intervention: Driver
Number of subjects: 353
Study 19389002 — intervention group
Group type: EXPERIMENTAL
Intervention: First 19 unsupervised procedures after training
Number of subjects: 3011
Study 19389002 — intervention group
Group type: EXPERIMENTAL
Intervention: Next 20-99 procedures
Number of subjects: 3011
Study 19389002 — intervention group
Group type: EXPERIMENTAL
Intervention: Last 100 procedures
Number of subjects: 3011
Study 16466358 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, developmentally supportive family-centered care
Number of subjects: 114
Study 16466358 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus individualized, developmentally supportive family-centered interventions
Number of subjects: 114
Study 16466358 — intervention group
Group type: COMPARATOR
Intervention: Routine neonatal intensive-care unit standard of care
Number of subjects: 114
Study 15307407 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention to improve skills of village drug kit managers
Number of subjects: 0
Study 15307407 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 0
Study 15307407 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention
Number of subjects: 0
Study 10392251 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue treatment
Number of subjects: 10
Study 8678535 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm T (THP + CPA + TAM)
Number of subjects: 0
Study 8678535 — intervention group
Group type: COMPARATOR
Intervention: Arm C (CPA + TAM)
Number of subjects: 0
Study 2072834 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) training (75% of heart rate reserve, approximately 82% VO2max, approximately 121% of lactate threshold)
Number of subjects: 17
Study 2072834 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity (LI) training (35% of heart rate reserve, approximately 53% VO2max, approximately 72% of lactate threshold)
Number of subjects: 17
Study 2072834 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 8)
Number of subjects: 17
Study 6441014 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard polyethylene catheter plus heparin
Number of subjects: 40
Study 6441014 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane catheter without heparin
Number of subjects: 40
Study 30879111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified regimen
Number of subjects: 0
Study 30879111 — intervention group
Group type: EXPERIMENTAL
Intervention: Received cumulative dose over time
Number of subjects: 0
Study 30879111 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in intensified regimen group
Number of subjects: 0
Study 30270762 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive aphasia therapy
Number of subjects: 0
Study 30270762 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 26811166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fat (20% energy), higher carbohydrate (65% energy) diet
Number of subjects: 245
Study 26811166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate (45% energy), higher fat (35% energy) diet
Number of subjects: 245
Study 26811166 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-rich, higher fat (35% energy), lower carbohydrate (45% energy) diet
Number of subjects: 245
Study 24820104 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete immunization schedule (7 vaccines and 15 doses)
Number of subjects: 26
Study 24820104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 24820104 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load rebound after cART interruption
Number of subjects: 26
Study 21987582 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (prednisolone sodium phosphate, 1.0%)
Number of subjects: 500
Study 21987582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 20661178 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 seroprevalence
Number of subjects: 5871
Study 20661178 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV18 seroprevalence
Number of subjects: 5871
Study 20661178 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 DNA prevalence
Number of subjects: 5871
Study 20661178 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV18 DNA prevalence
Number of subjects: 5871
Study 20661178 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with sexual behaviors
Number of subjects: 5871
Study 20661178 — intervention group
Group type: EXPERIMENTAL
Intervention: Assay cross-reactivity
Number of subjects: 5871
Study 20661178 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV18 seropositivity
Number of subjects: 5871
Study 20661178 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroprevalence over time
Number of subjects: 5871
Study 20661178 — intervention group
Group type: EXPERIMENTAL
Intervention: Serology as a measure of exposure
Number of subjects: 5871
Study 17567657 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin for 7 days (n = 126)
Number of subjects: 246
Study 17567657 — intervention group
Group type: COMPARATOR
Intervention: IV benzyl penicillin (n = 120)
Number of subjects: 246
Study 15718308 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐HART (70.6 Gy) with concurrent FU (600 mg/m(2), 120 hours continuous infusion) and MMC (10 mg/m(2))
Number of subjects: 384
Study 15718308 — intervention group
Group type: COMPARATOR
Intervention: HART (77.6 Gy)
Number of subjects: 384
Study 11928803 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant and adjuvant chemoradiation
Number of subjects: 72
Study 11928803 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical interventions (resection and reconstruction after esophagectomy)
Number of subjects: 72
Study 10450301 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 0
Study 10450301 — intervention group
Group type: COMPARATOR
Intervention: Control diet (typical American diet)
Number of subjects: 0
Study 10450301 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sodium intake
Number of subjects: 0
Study 10450301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate sodium intake
Number of subjects: 0
Study 10450301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower sodium intake
Number of subjects: 0
Study 7539701 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (5 days)
Number of subjects: 0
Study 7539701 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 days)
Number of subjects: 0
Study 2676220 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 1% at 2 mg.kg‐1
Number of subjects: 22
Study 2676220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 1.5 mg.kg‐1
Number of subjects: 22
Study 319697 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulators (functioning)
Number of subjects: 50
Study 319697 — intervention group
Group type: COMPARATOR
Intervention: Nonfunctioning machines (Control)
Number of subjects: 50
Study 31377534 — intervention group
Group type: EXPERIMENTAL
Intervention: Second Step Child Protection Unit (CPU)
Number of subjects: 2172